S. Murray Sherman to Disease-Free Survival
This is a "connection" page, showing publications S. Murray Sherman has written about Disease-Free Survival.
Connection Strength
0.325
-
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017 04; 75:213-221.
Score: 0.104
-
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Apr; 56(1):121-128.
Score: 0.103
-
Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015 Sep; 100(9):3270-9.
Score: 0.093
-
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4103-4109.
Score: 0.025